<DOC>
	<DOCNO>NCT01852942</DOCNO>
	<brief_summary>This study design test hypothesis treatment HIV infect subject losartan , agent specific anti-inflammatory anti-fibrotic action , : 1. reverse exist lymphoid tissue fibrosis , 2. restore lymphoid tissue architecture , 3. increase number improve function peripheral lymphatic CD4 T cell , 4. decrease level systemic immune activation ( IA ) , 5. decrease size HIV reservoir , 6. safe well tolerate .</brief_summary>
	<brief_title>Reversing Tissue Fibrosis Improve Immune Reconstitution HIV</brief_title>
	<detailed_description>This randomize , double-blind , placebo-controlled trial 50 HIV-1 infected individual stable ART randomize 1:1 ratio losartan ( 50 mg orally daily titrate 100 mg daily ) v placebo 30 month . We plan enroll total 63 HIV infected subject ensure 50 complete protocol . All HIV infect subject undergo biopsy inguinal lymph node ( LN ) gut associate lymphatic tissue ( GALT ) primary endpoint analysis baseline , 12 30 month study enrollment . Blood collect least quarterly throughout study intensive blood pharmacokinetic ( PK ) study conduct month 1 . All HIV infect subject vaccinate quadrivalent human papillomavirus ( HPV ) vaccine month 23 , 25 29.5 measure immune function . 5 HIV uninfected control subject also enrol . The primary endpoint determine impact losartan lymphoid tissue fibrosis HIV infect , ART treat adult . This determine measure amount collagen deposition lymphoid tissue integrity FRCn use immunohistochemistry ( IHC ) quantitative image analysis ( QIA ) .</detailed_description>
	<mesh_term>Infection</mesh_term>
	<mesh_term>Communicable Diseases</mesh_term>
	<mesh_term>Fibrosis</mesh_term>
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Acquired Immunodeficiency Syndrome</mesh_term>
	<mesh_term>Losartan</mesh_term>
	<criteria>HIV infect participant : 1 . Participants must meet follow inclusion criterion participate study : HIV1 infect . ≥ 18 year age . Baseline peripheral CD4+ T cell count 200600 cells/mm3 least two measure 6 month prior study enrollment . ≥ 12 month stable ART , define use give drug regimen without disruption last ≥ 1 week period lead study enrollment . HIV viral load ( VL ) &lt; 50 copies/mL least two consecutive measure 6 month prior study enrollment . No contraindication propose study procedure . Women childbearing potential must willing use form effective contraception duration study . Effective contraception include hormonal injection , implant oral medication , IUD , diaphragm , cervical cap spermicide . Condoms use sole form contraception . 2 . Participants meet follow exclusion criterion baseline exclude study participation : Use immunomodulator within 12 month prior study enrollment . An immunomodulator purpose study defined drug know either diminish augment patient 's immune system . Examples include , limited , systemic corticosteroid ( use topical steroid permit ) , TNFinhibitors , rituximab , cyclophosphamide , abatacept , cyclosporine , azathioprine , 6mercaptopurine , methotrexate , sulfasalazine , cyclosporine , tacrolimus , sirolimus , intravenous immune globulin . Current use ARB ACEi . Current use rifaximin , fluconazole lithium give potential drug interaction losartan . Prior reaction intolerance ARB ACEi . Prior diagnosis chronic inflammatory disease serologic clinical evidence diagnose primary care physician specialist . Examples include , limited , systemic lupus erythematosus , rheumatoid arthritis , scleroderma , Sjogren 's syndrome , mixed connective tissue disease , psoriasis , polymyositis , dermatomyositis , vasculitis , sarcoidosis , Wegener 's granulomatosis , giant cell arteritis , polyarteritis nodosa , gastrointestinal pemphigoid , eosinophilic colitis , Crohn 's disease , ulcerative colitis , autoimmune hepatitis , hepatitis C. Prior diagnosis connective tissue disease genetic , serologic clinical evidence diagnose primary care physician specialist ( Marfan 's syndrome , EhlersDanlos syndrome ) . Baseline blood pressure &lt; 110/70 . Estimated Glomerular Filtration Rate ( eGFR ) &lt; 30ml/min/1.73 m2 within 4 week study initiation history advance renal disease . AST and/or ALT &gt; 3 time upper limit normal within 4 week study enrollment . Potassium &gt; 5.0 within 4 week study enrollment . Pregnancy . In woman childbearing age , unwillingness use birth control duration study . Breast feeding . Prior vaccination HPV vaccine , include Cervarix ( GlaxoSmithKline ) Gardasil ( Merck ) . History hypersensitivity severe allergic reaction yeast . HIVuninfected : 1 . Inclusion Criteria Participants must meet follow inclusion criterion participate study : HIV uninfected . ≥ 18 year age . No contraindication propose study procedure . 2 . Participants meet follow exclusion criterion baseline exclude study participation : Use immunomodulator within 12 month prior study enrollment ( define ) . Current use ARB ACEi . Prior diagnosis chronic inflammatory disease serologic clinical evidence ( define ) . Prior diagnosis connective tissue disease genetic , serologic clinical evidence diagnose primary care physician specialist ( Marfan 's syndrome , EhlersDanlos syndrome ) . Pregnancy .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2016</verification_date>
	<keyword>Infection</keyword>
	<keyword>HIV 1</keyword>
	<keyword>HIV</keyword>
	<keyword>Losartan</keyword>
	<keyword>Fibrosis</keyword>
	<keyword>Immune Activation</keyword>
	<keyword>Immune Reconstitution</keyword>
</DOC>